|Interstitial Cystitis (IC)|
List of Completed Trials for Interstitial Cystitis (IC)Protocol Number: 42160443-PAI-2005 10/2010 - 03/2011
Sponsor: Johnson & Johnson
Title: A Randomized Double-Blind, Placebo-Controlled Study to Explore The Efficacy, Safety, and Tolerability of JNJ-42160443 In Subjects With Interstitial Cystitis/ Painful Bladder Syndrome
Protocol Number: A0708 06/2009 -- 12/2009
Sponsor: ICDX Corporation
Title: A comparison of Sialic Acid content of tamm-horsfall protein (THP) in the urine of asymptomatic control subjects versus interstitial cystitis (IC) / Painful Bladder syndrome (PBS) patients.
Protocol Number: JIC01 01/2003 09/2003
Title: A Phase 2, randomized, double-blind, placebo-controlled study of the safety and efficacy of RTX topical solution in the reduction of pain for patients with interstitial cystitis.
Protocol Number: ANS C-04-05 05/2006 03/2008
Sponsor: Advanced Neuromodulation Systems
Title: A pilot study to evaluate sacral nerve root stimulation for the treatment of chronic pelvic pain due to interstitial cystitis.
Protocol Number A4091010 02/2008 - 05/2009
Sponsor: Pfizer, Inc.
Title: A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of Pf-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis.
Clinical Research Coordinators:
Lisa Bennett, RN or Michelle Utrera, CMA, EMT (336) 274-1114 ext. 5322
E-mail address: email@example.com
Protocol Number: TAR-100-202 03/2013 - Present
Title: A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS 400mg in Women with Interstitial Cystitis Followed by an Open Label Extension.
Purpose of Study
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.